HPV AND ANTIGEN PRESENTING CELLS
HPV AND ANTIGEN PRESENTING CELLS
批准号:
9175994
负责人:
WIJBE MARTIN KAST
金额:
$35.27万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-06-01 至 2021-07-31
关键词:
3-DimensionalAcidsAnnexinsAntigen PresentationAntigen-Presenting CellsAntiviral AgentsAnusBiochemicalBiologicalBiological AssayBirbeck GranuleCancer EtiologyCell MaturationCell surfaceCellsCellular biologyCervicalDataDetectionDevelopmentDiseaseElectronsEpithelialEpithelial CellsEpitheliumEventFigs - dietaryFluorescence MicroscopyFutureGasesGenesGenotypeGoalsHead and Neck CancerHealthHumanHuman PapillomavirusHuman papilloma virus infectionHuman papillomavirus 16ImmuneImmune responseImmune systemImmunologic SurveillanceIn VitroInfectionInvadedKnowledgeLangerhans cellLeadLesionLysineMalignant NeoplasmsMediatingMembraneMicroscopicModelingMorbidity - disease rateOrganellesPeptidesPhosphoproteinsPoly ICLCPopulationPreventionPreventive vaccineProcessProteinsProxyPublic HealthRoleSignal PathwaySignal TransductionSiteSkinStimulusStructureSystemT-LymphocyteTestingTissuesTranslatingTransmission Electron MicroscopyVaginaViralVirusWomanantigen processingbaseclinical investigationcofactorcytokinedesignhigh riskimmune functionimmunocytochemistryin vivoinhibitor/antagonistinnovationinsightknock-downlangerinmortalitynovelnovel strategiespathogenpre-clinicalpreventprotein protein interactionreceptorresponsesingle moleculetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Human papillomaviruses (HPV) are common sexually transmitted viruses and their infections are a significant
health burden for the population. Persistent infection with high-risk HPV genotypes result in the development of
a variety of human cancers, most prominently cervical, anal, and subtypes of head and neck cancers. HPV
establishes persistent infection within the host through evasion of the immune system. One of the ways HPV
accomplishes this is by manipulating Langerhans cells (LC), which are the antigen presenting cells at the site
of infection that are responsible for initiating immune responses against epithelium invading viruses. The
interaction of HPV with LC through the annexin A2 heterotetramer (A2t) and subsequent suppressive signaling
events act as a braking mechanism that stops LC activation, resulting in incomplete LC maturation and
prevention of an effective antiviral T cell immune response. Our long-term goals are to understand how HPV
manipulates LC activation and antigen processing to evade the immune system and test new ways to treat
HPV-associated diseases. AIM 1 will focus on the effects of utilizing a “brakes off, gas pedal down”
combination approach for activating LC exposed to HPV. This will be investigated through cell surface marker
and cytokine analysis and functional immunological assays. AIM 2 will investigate the signaling pathways and
A2t interaction partners associated with A2t-mediated suppression of LC immune function that are hijacked by
HPV using biochemical and cell biological approaches. This will be analyzed through broad interrogation of
phosphoprotein activation and cell signaling networks, antigen presenting cell specific profiling gene arrays,
and a newly developed Single Molecule Pulldown (SiMPull) assay. AIM 3 will evaluate the contribution of A2t
to LC Birbeck granule structure, function, and role in HPV antigen processing. This will be investigated through
immuno-electron microscopic analysis of Birbeck granule components in LC, assessment of A2t protein
knockdown effects on Birbeck granule formation, and elucidation of the effects of protein knockdown on the
ability of LC to properly process and present HPV-derived peptides to HLA-matched T cell clones. Additionally,
these aims will utilize innovative skin explant and 3-D culture systems to validate that the proposed HPV16-A2t
interactions are important for LC biology in vivo. Collectively the proposed studies will provide deep insight into
basic LC biology and function. In addition we will examine the effects of a novel two-pronged approach focused
on preventing negative signaling events in LC while simultaneously providing a positive stimulus to activate LC
as a novel strategy to treat HPV infections, thereby preventing HPV-associated cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploration of novel pan-HPV treatments to block development of AIDS-associated c
-
批准号:7854118
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:WIJBE MARTIN KAST
-
依托单位:
Exploration of novel pan-HPV treatments to block development of AIDS-associated c
-
批准号:7944126
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:WIJBE MARTIN KAST
-
依托单位:
PAPILLOMA VLP IMMUNIZATION AGAINST HPV-TRANSFORMED CELLS
-
批准号:6481881
-
项目类别:
-
资助金额:$25.41万
-
财政年份:2001
-
负责人:WIJBE MARTIN KAST
-
依托单位:
PAPILLOMA VLP IMMUNIZATION AGAINST HPV-TRANSFORMED CELLS
-
批准号:6318307
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2000
-
负责人:WIJBE MARTIN KAST
-
依托单位:
PAPILLOMA VLP IMMUNIZATION AGAINST HPV-TRANSFORMED CELLS
-
批准号:6103360
-
项目类别:
-
资助金额:$15.12万
-
财政年份:1999
-
负责人:WIJBE MARTIN KAST
-
依托单位:
IMMUNE SUPPRESSION AND IMMUNE ESCAPE IN TUMOR MODELS
-
批准号:6376821
-
项目类别:
-
资助金额:$24.62万
-
财政年份:1998
-
负责人:WIJBE MARTIN KAST
-
依托单位:
IMMUNE SUPPRESSION AND IMMUNE ESCAPE IN TUMOR MODELS
-
批准号:2896559
-
项目类别:
-
资助金额:$23.5万
-
财政年份:1998
-
负责人:WIJBE MARTIN KAST
-
依托单位:
IMMUNE SUPPRESSION AND IMMUNE ESCAPE IN TUMOR MODELS
-
批准号:6173795
-
项目类别:
-
资助金额:$24.05万
-
财政年份:1998
-
负责人:WIJBE MARTIN KAST
-
依托单位:
IMMUNE SUPPRESSION AND IMMUNE ESCAPE IN TUMOR MODELS
-
批准号:2670924
-
项目类别:
-
资助金额:$22.96万
-
财政年份:1998
-
负责人:WIJBE MARTIN KAST
-
依托单位:
PAPILLOMA VLP IMMUNIZATION AGAINST HPV-TRANSFORMED CELLS
-
批准号:6269836
-
项目类别:
-
资助金额:$15.39万
-
财政年份:1998
-
负责人:WIJBE MARTIN KAST
-
依托单位:
VLP VACCINES AGAINST HPV INDUCED TUMORS
-
批准号:6376426
-
项目类别:
-
资助金额:$21.62万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
VLP vaccines against HPV-induced tumors
-
批准号:6466493
-
项目类别:
-
资助金额:$29.64万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
VLP vaccines against HPV-induced tumors
-
批准号:6722933
-
项目类别:
-
资助金额:$32.52万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
HPV AND ANTIGEN PRESENTING CELLS
-
批准号:9303290
-
项目类别:
-
资助金额:$35.27万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
HPV VLP AND ANTIGEN PRESENTING CELLS
-
批准号:7785140
-
项目类别:
-
资助金额:$32.63万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
VLP vaccines against HPV-induced tumors
-
批准号:6886703
-
项目类别:
-
资助金额:$32.54万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
VLP vaccines against HPV-induced tumors
-
批准号:7037655
-
项目类别:
-
资助金额:$31.85万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
HPV AND ANTIGEN PRESENTING CELLS
-
批准号:9978719
-
项目类别:
-
资助金额:$42.05万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
HPV VLP AND ANTIGEN PRESENTING CELLS
-
批准号:8704111
-
项目类别:
-
资助金额:$30.7万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
HPV VLP AND ANTIGEN PRESENTING CELLS
-
批准号:8300170
-
项目类别:
-
资助金额:$31.65万
-
财政年份:1997
-
负责人:WIJBE MARTIN KAST
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: